SAN FRANCISCO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ:QDEL) investors who suffered substantial losses to submit your losses now.
Visit: www.hbsslaw.com/investor-fraud/QDEL
Contact An Attorney Now: QDED@hbsslaw.com
844-916-0895
QuidelOrtho Corporation (NASDAQ:QDEL) Investigation:
"We're investigating whether QuidelOrtho may have potentially misrepresented or concealed the true extent of the deterioration in its respiratory revenue," said Reed Kathrein, the Hagens Berman partner leading the investigation.
Specifically, QuidelOrtho management said as recently as Nov. 1, 2023 that "[w]e expect respiratory revenue to be at the upper end of our range of $610 million to $775 million for Q4[]" and "to get to the high end of the range that respiratory revenue that I talked about in the prepared remarks, you're looking to increase ...
QDEL) Stock Crashes After Posting YoY Revenue Decline, Analyst Downgrades - Hagens Berman>Full story available on Benzinga.com